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Natural killer (NK) cells represent an attractive lymphocyte population for cancer
immunotherapy due to their ability to lyse tumor targets without prior sensitization and
without need for human leukocyte antigens-matching. Chimeric antigen receptors (CARs)
are able to enhance lymphocyte targeting and activation toward diverse malignancies.
CARs consist of an external recognition domain (typically a small chain variable fragment)
directed at a specific tumor antigen that is linked with one or more intracellular signaling
domains that mediate lymphocyte activation. Most CAR studies have focused on their
expression in T cells. However, use of CARs in NK cells is starting to gain traction because
they provide a method to redirect these cells more specifically to target refractory cancers.
CAR-mediated anti-tumor activity has been demonstrated using NK cell lines, as well as
NK cells isolated from peripheral blood, and NK cells produced from human pluripotent
stem cells. This review will outline the CAR constructs that have been reported in NK
cells with a focus on comparing the use of different signaling domains in combination
with other co-activating domains.
Keywords: chimeric antigen receptors, natural killer cells, cancer immunotherapy, NK-92 cells, induced pluripotent
stem cells
Introduction
Natural killer (NK) cells are an important component of the innate immune system due to
their ability to lyse infected or malignant cells without prior sensitization and without human
leukocyte antigens (HLA)-restriction (1). They play an important role in immune surveillance
and early control of many malignancies. NK cells recognize infected or transformed cells through
multiple cell surface receptors including NKG2D, CD16 [the receptor that mediates antibody-
dependent cellular cytotoxicity (ADCC)], and natural cytotoxicity receptors (NCRs) such as NKp44,
NKp46, and NKp30 (2). These receptors activate signaling adapter proteins such as DAP10,
DAP12, and CD3ζ, which contain immuno-tyrosine activation motifs (ITAMs) that initiate the
release of cytolytic granules containing perforin and granzymes, as well as mediate production
and release of cytokines and chemokines such as IFN-γ and TNF-α (3). Importantly, NK cell-
mediated cytotoxicity does not rely on the presentation of self HLA. Therefore, NK cells hold
significant clinical interest as a cell-based therapy for cancer because of their ability to be used
in an allogeneic setting and potentially provide an off-the-shelf cellular product. Clinical trials
using NK cells obtained from haploidentical donors demonstrate long-term remissions in patients
with refractory acute myelogenous leukemia (4). Trials against solid tumors such as breast cancer
and ovarian cancer have also demonstrated efficacy (5). NK cell lines (NK-92 cells) (6) and NK
cells derived from umbilical cord blood (7) have also been tested in clinical trials (NCT01729091,
NCT02280525).
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Chimeric antigen receptors (CARs) are engineered proteins
designed to activate lymphocytes, particularly T cells, upon target
recognition. CARs contain a single-chain variable fragment (scFv)
fused to a variety of possible intracellular signaling domain(s).
The scFv is designed to target antigens either overexpressed or
unique to tumor cells. The signaling domain initially tested was
the ζ chain of the T cell receptor complex CD3 in first generation
CARs (8). Second generation CARs employ co-activating proteins
such as CD28, CD137 (4-1BB), or CD134 (OX40) in combination
with CD3ζ to increase T cell activation and proliferation (9,
10). Finally, CAR constructs incorporate multiple co-activation
domains andCD3ζ in the third generationCARs (11). The clinical
success of anti-CD19 CAR-expressing T cells for treatment of B-
cell malignancies has fueled the design and evaluation of CARs
for T cell therapy toward other antigens and malignancies (12).
While development of T cell-CAR-based therapies seems to be
revolutionizing tumor immunotherapy, one major obstacle with
this approach is the need to collect and utilize autologous cells.
A second concern with the use of T cells is their long-term
persistence, resulting in chronic on-target-off-tumor effects such
as B-cell aplasia with the anti-CD19 CARs being used currently in
clinical trials.
Natural killer cells provide an alternative to the use of T cells for
adoptive immunotherapy since they do not require HLA match-
ing, so can be used as allogeneic effector cells (13). Clinical trials
of adoptively transferred allogeneic NK cells demonstrate these
cells can survive in patients for several weeks to months (4, 13).
Additionally, expression of CARs in NK cells may allow these
cells to more effectively kill solid tumors that are often resistant to
NK cell-mediated activity compared to hematologic malignancies
(especially acute myelogenous leukemia) that are typically more
NK cell-sensitive (4, 5). As such, CAR-expressing NK cells have
gained significant interest to provide a targeted, allogeneic, “uni-
versal” cell population for treatment of refractory malignancies.
This review will focus on the CAR constructs and activating
domains that have been reported to be used in NK cell lines (such
as NK-92 cells) and peripheral blood (PB) NK cells. Additional
work using NK cells produced from human pluripotent stem cells
is also discussed.
Chimeric Antigen Receptors Used in NK
Cell Lines
Natural killer cell lines have been utilized to evaluate CARs
targeting several different antigens. By far, the most commonly
studied NK cell line has been the NK-92 cell line, which has
been previously (6) and is currently being used in clinical trials
(NCT00900809 and NCT00990717). Other NK cell lines include
NKG, YT, NK-YS, HANK-1, YTS cells, and NKL cells (14).Work-
ing with NK cell lines has several advantages such as providing a
more homogeneous cell population compared to NK cells isolated
from PB. In addition, the NK-92 cells have been well-defined
and there is no need to perform any isolation of the NK cells
from donors. However, NK cell lines also have distinct disadvan-
tages. NK-92 cells lack the expression of several typical NK cell
activating receptors such as CD16, NKp44, and NKp46 (15, 16).
Also, NK-92 cells are tumor cell lines with multiple cytogenetic
TABLE 1 | CAR constructs utilized in NK cell lines (NK-92).
Reference Target CAR Construct Method
(23) ErbB2 (HER-2) mCD8α hinge/CD3ζ Amphotropic virus
(19) CD20 mCD8α hinge/CD3ζ Amphotropic virus
(22) CD19 CD8α TM/CD3ζ mRNA transfection
(50%)
(30) EpCAM CD8α
hinge/CD28/CD3ζ
Lentivirus along with
IL-15
(31) HLA-A2 EBNA3C CD8α
TM/CD137/CD3ζ
Retrovirus
(26) GD2 mCD8α hinge/CD3ζ Amphotropic virus
(20) CD19/CD20 CD3ζ mRNA transfection
(30–70%) and
lentivirus
(28) HLA-2 complex
with melanoma-
associated gp100
peptide
A2 TM/CD3ζ Transfection
(21) CD19/CD20 CD3ζ Lentivirus
(32) CS1 CD28
TM/CD28/CD3ζ
Lentivirus
(27) CD138 CD8α hinge/CD3ζ Lentivirus
(24) ErbB2 (HER-2) CD8α
hinge/CD28/CD3ζ
Transfection
(25) ErbB2 (HER-2) CD8α hinge/CD3ζ Lentivirus
CD8α
hinge/CD28/CD3ζ
CD8α
hinge/CD137/CD3ζ
(34) PSCA CD28 hinge/CD28
TM/CD3ζ
Lentivirus in YTS NK
cells and primary NK
cellDAP12 TM and
signaling
abnormalities (17) and are latently infected with Epstein–Barr
virus (18). Therefore, for safety purposes, these cells must be
irradiated prior to infusion.
The majority of studies to express CARs in NK-92 cells have
used first generation CAR constructs that contain CD3ζ as their
sole signaling domain. The scFvs of these CARs have targeted
CD20 (19–21), CD19 (20–22), ErbB2 (HER2) (23–25), GD2
(26), and CD138 (27) (Table 1). In addition to directly target-
ing cell surface proteins, CARs can also recognize HLA-peptide
complexes such as HLA-A2 expressing the melanoma-associated
gp100 peptide (28). CARs directed toward CD19 and CD20 are
designed to target B-cell malignancies and have also been studied
extensively in T cells (29). The only other difference in the anti-
CD19 or anti-CD20 CAR constructs used in NK-92 cells is the
transmembrane region. One study used the CD3ζ transmem-
brane sequence (19) while another used the CD8 transmem-
brane sequence (22). However, without a direct comparison it
is unknown if one construct is superior. Another study used an
HLA-A2 transmembrane region coupled to a CD3ζ signaling
domain (28), suggesting the transmembrane region may be eas-
ily altered without impacting CAR expression and functionality.
Interestingly, comparison of CAR transfected NK-92 cells with
ADCC function using NK-92 cells engineered to express CD16
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found that the anti-CD20 CAR engineered cells lysed primary
CLL cells more effectively thanNK-92 cells acting through ADCC
using rituximab (21). This study suggests that even first generation
CARs may be an improvement over ADCC-mediated anti-tumor
activity by NK-92 cells. It is important to note that NK-92 cells
require transfection of CD16 in order to perform ADCC. This
leaves open the possibility that PB-NK cells may still be better
equipped to perform ADCC better than NK-92 cells.
Solid tumor antigens can also be targeted by first generation
CAR constructs expressed in NK-92 cells. An anti-ErbB2 CAR
construct against HER2-positive breast, ovarian, and squamous
cell carcinoma cell lines mediated improved killing ability of NK-
92 cells (23). Additionally, this study showed a reduction in tumor
growth using ErbB2-expressing NIH 3.3 cells mixed with NK-
92s in a subcutaneous mouse model (23). An anti-GD2 CAR
using just the CD3ζ transmembrane and signaling domains was
able to target primary glioblastoma cells as well as GD2-positive
melanoma and breast carcinomas (26). NK-92 cells can also be
targeted against multiple myeloma (MM) using an anti-CD138
CAR with only CD3ζ as a signaling domain (27). Notably, mice
bearing a subcutaneous tumor treated with CAR-expressing NK-
92 cells survived significantly longer than NK-92 cell alone in a
CD138-positive tumor model; whereas, when a CD138-negative
MM tumor was used no difference was detected (27). These data
clearly demonstrate that first generation CARs are an effective
means to induce target cell lysis in NK-92 cells both in vitro and in
mouse models; however, many of the tumor models are subcuta-
neous, whichmay fail to properly recapitulate the complete tumor
environment or NK cell trafficking issues.
Second generation CARs expressing a second signaling domain
in conjunction with CD3ζ vastly improves the overall activ-
ity CAR-expressing T cells (9). This has generated interest in
using second generation CARs in NK cells. Similar to first
generation CARs, several different scFvs have been used with
second generation CARs including EpCAM for multiple carci-
nomas including breast and ovarian cancer (30), an HLA-A2
EBNA3C complex for Epstein–Barr virus (31), CS1 for MM (32),
and ErbB2 for HER2 positive cancers (24, 25). The most common
second generation CAR utilized in NK-92 cells pairs the CD28
intracellular domain with CD3ζ (Table 1). Notably, NK cells do
not naturally express CD28 (35); therefore, the effect that this
domain has in NK cells is unclear. Other second generation CARs
combine CD137 (4-1BB) intracellular domain with CD3ζ. Similar
to first generation CARs, all of the constructs lead to antigen
specific killing of target cells, displaying the diverse set of tumor
antigens CARs can target. Comparison of an ErbB2 scFv fused
with CD3ζ alone, CD28/CD3ζ, or CD137/CD3ζ tested head-to-
head against breast cancer cells found that both of the second
generation constructs improved killing compared to the first gen-
eration CARs (25). Specifically, the CD28/CD3ζ had 65% tar-
get lysis in ErbB2-positive MDA-MB453 while the CD137/CD3ζ
lysed 62% and CD3ζ alone killed 51% (25). Another modification
in their construct design was the modification of a cysteine to
a serine in the CD8α signaling peptide used, which the authors
suggest improves surface expression of the CAR in NK-92 cells.
Finally, CD28/CD3ζ was compared to DAP12 alone using an
anti-PSCA CAR in YTS NK cells for prostate cancer (34). In 293T
cell lines engineered to express PSCA, a significant increase in cell
killing was observed with the DAP12 containing CAR compared
to the CD28/CD3ζ CAR, suggesting DAP12 may provide a better
signaling domain than CD3ζ (34).
Chimeric Antigen Receptor use in
Peripheral Blood NK Cells
Chimeric antigen receptors have also been evaluated in PB-NK
cells, which can be isolated from donors through simple blood
draws or by apheresis if larger numbers of cells are needed. In
contrast to NK-92 cells, activated PB-NK cells express a wider
range of activating receptors, such as CD16, NKp44, and NKp46
as well as KIRs, which play an important role in NK cell licensing
(36). In addition, PB-NK cells can be given without irradiating
the cells so have the ability to expand in vivo, which has been
correlated with effectiveness in trials involving AML (4). A greater
variety of CAR constructs have been used and directly compared
in PB-NK cells targeting CD19 (37–39), CD20 (33), or ErbB2 (40,
41) (Table 2). Imai et al. describe the use of two first generation
anti-CD19 CARs, CD3ζ, or DAP10 signaling, and one second
generation CAR with CD137 and CD3ζ. Compared to CD3ζ,
DAP10 induced a much weaker response in PB-NK cells, and
addition of the CD137 domain to the CAR resulted in augmented
killing of RS4:11 and 380 (ALL) cell lines (37). Another study
compared CD3ζ or 2B4 alone, 2B4 combined with CD3ζ, and
a CD137/CD3ζ anti-CD19 CAR and tested them against the
leukemic cell line REH. In vitro studies demonstrated the 2B4
alone CAR was slightly less active compared to CD3ζ alone.
Comparing the second generation CARs, both were significantly
better than CD3ζ alone while similar activity was observed in the
2B4/CD3ζ and CD137/CD3ζ CARs (38). When this work was
extended to an anti-GD2 CAR for neuroblastoma with just the
CD3ζ and 2B4/CD3ζ endodomains, again the 2B4/CD3ζ was sig-
nificantly better than CD3ζ alone (38). Another study compared
CD3ζ alone with a CD28/CD3ζ CAR using ErbB2 as a target.
TABLE 2 | CAR constructs utilized in PB-NK cells.
Reference Target CAR construct Method
(37) CD19 CD8α TM/CD3ζ Retrovirus (mean 69%)
CD8α TM/DAP10
CD8α
TM/CD137/CD3ζ
(40) ErbB2 (HER-2) CD28/CD3ζ Retrovirus (mean 55%)
(38) CD19/GD2 CD3ζ or 2B4 alone Retrovirus (13–24%)
2B4/CD3ζ
CD8 TM/CD137/CD3ζ
(39) CD19 CD137/CD3ζ Transfection (mRNA)
(mean 58%)
(42) NKG2D
ligands
NKG2D/CD3ζ
co-expressed with
DAP10
Retrovirus and mRNA
transfection
(41) ErbB2 (HER-2) CD3ζ alone Retrovirus (40–50%)
CD28/CD3ζ
(33) CD20 CD137/CD3ζ Transfection (mRNA)
(50–95%)
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While no direct lysis experiment was performed, similar levels
of INF-γ production were observed in PB-NK cells engineered
with just CD3ζ or CD28/CD3ζ (41). While different measures
were used, the finding that CD28/CD3ζ does not improve activity
in PB-NK cells whereas the same construct was found to be
more active in NK-92 suggests there may be differences in CAR
activation of PB-NK and NK-92 cells.
One unique approach to CAR creation was to use the
ectodomain of NKG2D, an NK cell activation receptor, and link
it directly to CD3ζ (42). This approach utilizes natural NKG2D
ligands commonly overexpressed on malignant cells to active
the CAR. Further, NKG2D associates with DAP10 providing a
secondary signaling molecule. Indeed, co-expression of DAP10
with the NKG2D/CD3ζ CAR increased surface expression. This
CAR was tested against multiple cell lines derived from several
malignancies with the best responses demonstrated against ALL,
osteosarcoma, prostate carcinoma, and rhabdomyosarcoma (42).
A third source of NK cells suitable for CAR expression are NK
cells derived from human pluripotent stem cells – both induced
pluripotent stem cells (iPSCs) or human embryonic stem cells
(hESCs) (43–47). These NK cells display a similar phenotype to
PB-NK cells (43, 44, 48), and hESC/iPSC-NK cells can be grown
on a clinical scale (48). iPSC-derived NK cells engineered with
a CD4/CD3ζ CAR are able to inhibit HIV replication (49). In
these studies, the CAR was expressed in the iPSC cells, which
were then differentiated into CAR-expressing iPSC-NK cells. The
CD4/CD3ζ iPSC-NK cells were shown to suppress the in vitro
replication of HIV, providing a platform from which to work for
the further development of CAR positive iPSC-NK cells. iPSC-
derivedNK cells combine the best of PB-NK andNK-92 cells since
the cells express NKp44, NKp46, and KIRs, are a homogeneous
population with no evidence of undifferentiated iPSCs or T cells
in the expanded NK cell population. Additionally, CARs can be
easily expressed in hESC and/or iPSC-derivedNK cells using non-
viral gene transfer methods (49, 50). This is in contrast to PB-NK
cells that are much more challenging to achieve high levels of
stable CAR expression.
Outlook
As the interest in using CARs in not only T cells (10) but also
in NK cells continues to grow, there are still a number of ques-
tions that remain to be answered. Perhaps most important is
what CAR constructs mediate optimal anti-tumor (or anti-viral)
activity. Limited studies inNK-92 cells and in PB-NK cells directly
compare first and second generation CARs. Second generation
CARs in PB-NK cells are generally more active than first gen-
eration CARs. Additionally, the use of CD3ζ seems better than
DAP10 as the signaling domain (37, 38). In NK-92 cells, DAP12
outperformed a CD28/CD3ζ CAR, but it remains unclear if NK-
92 cells provide a good model for how CARs may function in
PB-NKcells or hESC/iPSC-derivedNKcells. SinceNKcells do not
naturally express CD28 (35, 51), it is not clear if CD28 is function-
ing in CAR-expressing NK cells. Different CAR constructs may
be required to provide optimal NK cell activation depending on
the tumor type or target antigen. More direct comparisons using
various intracellular signaling domains and scFvs are needed to
best resolve these questions.
Additional research is also needed to determine whether use
of an NK cell line (such as NK-92 cells), PB-NK cells, or iPSC-
NK cells will provide the best overall benefit. Both 4-1BBL/IL-15
(52) and mbIL-21 (53) artificial antigen presenting cells (aAPCs)
can be used to expand PB-NK or iPSC-NK cells (48). Therefore,
production of enough NK cells from these sources for clinical
use is not a problem. However, it remains to be determined if
one aAPC leads to an improved population for adoptive trans-
fer, and the methods to engineer PB-NK cells still need to be
further improved. iPSC-NK cells represent an attractive pop-
ulation of cells for NK-CAR therapy because once engineered
the iPSC line can be maintained indefinitely and provide an
almost limitless supply of NK cells. In addition, careful moni-
toring of the insertion site of the CAR can be achieved. Finally,
NK cell lines provide another alternative but in general express
fewer natural NK cell receptors and must be irradiated prior to
infusion, which limits in vivo expansion and persistence of NK
cells.
The method for CAR incorporation provides another impor-
tant consideration. To get stable expression of CARs, retro- and
lentivirus methods have dominated. However, following trans-
duction of NK-92 cells a selection step is usually required to get a
pure CAR-expressing population. In PB-NK cells, the efficiencies
of gene transfer were at best 69% (37) and ranged as low as 13–24%
(38) with most reporting around a 50% transduction efficiency.
One way around this issue is the possibility of expressing the CAR
in iPSCs and subsequent differentiation intomature NK cells (49),
which is done via nucleofection with transposon and avoids the
hazards of viral methods. Another consideration is whether the
use of suicide systems, such as Cas9 or thymidine kinase (TK),
will need to be put in place if unexpected toxicities arise despite
the expectation that CAR-expressing NK cells will only circulate
for a few weeks (14).
Despite the questions that remain, the ability to engineer
NK cells with CARs holds great promise as a novel cellu-
lar immunotherapy against refractory malignancies and poten-
tially chronic infectious diseases. The success of T cell-CARs
in cases of ALL and CLL has revolutionized the prospects for
cell-based immunotherapy. CAR-NK cells can build upon this
success to provide important benefits as CAR-based therapy
expands. Notably, NK cells can provide a homogenous, off-
the-shelf, standardized product that can be used in as an allo-
geneic product to treat patients. Therefore, this process does not
need to be done on a patient-specific basis, as with current T
cell-CAR-based therapies. The ability to more potently direct
NK cell-mediated cytotoxicity against refractory tumors through
the expression of CARs can continue to revolutionize cancer
treatment.
Author Contributions
DH performed the review of the literature and wrote the
manuscript. DK wrote and edited the manuscript.
Acknowledgments
DH Ph.D., would like to acknowledge the Cancer Research Insti-
tute for support through the Irvington Postdoctoral Fellowship
award.
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1954
Hermanson and Kaufman NK cell-based CARs
References
1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al.
Innate or adaptive immunity? The example of natural killer cells. Science (2011)
331:44–9. doi:10.1126/science.1198687
2. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natu-
ral killer cell responses: integration of signals for activation and inhibition.
Annu Rev Immunol (2013) 31:227–58. doi:10.1146/annurev-immunol-020711-
075005
3. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition.Nat
Immunol (2008) 9:495–502. doi:10.1038/ni1581
4. Miller JS, Soignier Y, Panoskaltsis-Mortari A, Mcnearney SA, Yun GH, Fautsch
SK, et al. Successful adoptive transfer and in vivo expansion of human hap-
loidentical NK cells in patients with cancer. Blood (2005) 105:3051–7. doi:10.
1182/blood-2004-07-2974
5. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A
phase II study of allogeneic natural killer cell therapy to treat patients with
recurrent ovarian and breast cancer. Cytotherapy (2011) 13:98–107. doi:10.
3109/14653249.2010.515582
6. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al.
Treatment of patients with advanced cancer with the natural killer cell line
NK-92. Cytotherapy (2013) 15:1563–70. doi:10.1016/j.jcyt.2013.06.017
7. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, DeWitte T, et al.
Clinical-grade generation of active NK cells from cord blood hematopoietic
progenitor cells for immunotherapy using a closed-system culture process.PLoS
One (2011) 6:e20740. doi:10.1371/journal.pone.0020740
8. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell
receptor chimeric molecules as functional receptors with antibody-type
specificity. Proc Natl Acad Sci U S A (1989) 86:10024–8. doi:10.1073/pnas.86.
24.10024
9. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric anti-
gen receptor design. Cancer Discov (2013) 3:388–98. doi:10.1158/2159-8290.
CD-12-0548
10. Jena B, Moyes JS, Huls H, Cooper LJ. Driving CAR-based T-cell therapy to suc-
cess. Curr Hematol Malig Rep (2014) 9:50–6. doi:10.1007/s11899-013-0197-7
11. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM,
et al. Control of large, established tumor xenografts with genetically retargeted
human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A
(2009) 106:3360–5. doi:10.1073/pnas.0813101106
12. Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go?
Cancer J (2014) 20:151–5. doi:10.1097/PPO.0000000000000032
13. Vivier E, Tomasello E, BaratinM,Walzer T, Ugolini S. Functions of natural killer
cells. Nat Immunol (2008) 9:503–10. doi:10.1038/ni1582
14. GlienkeW, Esser R, Priesner C, Suerth JD, SchambachA,WelsWS, et al. Advan-
tages and applications of CAR-expressing natural killer cells. Front Pharmacol
(2015) 6:21. doi:10.3389/fphar.2015.00021
15. Gong JH,Maki G, KlingemannHG. Characterization of a human cell line (NK-
92) with phenotypical and functional characteristics of activated natural killer
cells. Leukemia (1994) 8:652–8.
16. Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the
cytotoxic activity of the humannatural killer cell line,NK-92. J Hematother Stem
Cell Res (2001) 10:369–83. doi:10.1089/152581601750288975
17. MacLeod RA, Nagel S, Kaufmann M, Greulich-Bode K, Drexler HG.
Multicolor-FISH analysis of a natural killer cell line (NK-92). Leuk Res (2002)
26:1027–33. doi:10.1016/S0145-2126(02)00055-3
18. Uphoff CC, Denkmann SA, Steube KG, Drexler HG. Detection of EBV, HBV,
HCV,HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J Biomed Biotechnol (2010) 2010:904767. doi:10.1155/2010/904767
19. Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG,
et al. Expression of a CD20-specific chimeric antigen receptor enhances cyto-
toxic activity of NK cells and overcomes NK-resistance of lymphoma and
leukemia cells. Cancer Immunol Immunother (2008) 57:411–23. doi:10.1007/
s00262-007-0383-3
20. Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, et al. Com-
parison of mRNA and lentiviral based transfection of natural killer cells with
chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma
(2012) 53:958–65. doi:10.3109/10428194.2011.634048
21. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS,
et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric
antigen receptors compares favorably with antibody-dependent cellular cyto-
toxicity. Oncoimmunology (2013) 2:e26527. doi:10.4161/onci.26527
22. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with
mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated
killing of CLL cells. Leuk Res (2009) 33:1255–9. doi:10.1016/j.leukres.2008.11.
024
23. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al.
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer
cells results in efficient and selective tumor cell destruction. Blood (2002)
100:1265–73.
24. Liu H, Yang B, Sun T, Lin L, Hu Y, Deng M, et al. Specific growth inhibition
of ErbB2-expressing human breast cancer cells by genetically modified NK-92
cells. Oncol Rep (2015) 33:95–102. doi:10.3892/or.2014.3548
25. Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M,
et al. Selective inhibition of tumor growth by clonal NK cells expressing an
ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2015) 23:330–8.
doi:10.1038/mt.2014.219
26. Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, et al. NK cells
engineered to express a GD2-specific antigen receptor display built-in ADCC-
like activity against tumour cells of neuroectodermal origin. J Cell Mol Med
(2012) 16:569–81. doi:10.1111/j.1582-4934.2011.01343.x
27. Jiang H, ZhangW, Shang P, Zhang H, FuW, Ye F, et al. Transfection of chimeric
anti-CD138 gene enhances natural killer cell activation and killing of multiple
myeloma cells.Mol Oncol (2014) 8:297–310. doi:10.1016/j.molonc.2013.12.001
28. Zhang G, Liu R, Zhu X,Wang L, Ma J, Han H, et al. Retargeting NK-92 for anti-
melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol
(2013) 91:615–24. doi:10.1038/icb.2013.45
29. Ghorashian S, Pule M, Amrolia P. CD19 chimeric antigen receptor T cell
therapy for haematological malignancies. Br J Haematol (2015). doi:10.1111/
bjh.13340
30. Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in
rapid enrichment and selective cytotoxicity of gene-modified effectors that
carry a tumor-specific antigen receptor. Cancer Immunol Immunother (2012)
61:1451–61. doi:10.1007/s00262-012-1212-x
31. Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-
A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther
(2012) 19:84–100. doi:10.1038/cgt.2011.66
32. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific
chimeric antigen receptor (CAR)-engineered natural killer cells enhance
in vitro and in vivo antitumor activity against human multiple myeloma.
Leukemia (2014) 28:917–27. doi:10.1038/leu.2013.279
33. Chu Y, Hochberg J, Yahr A, Ayello J, Van De Ven C, Barth M, et al. Targeting
CD20+ aggressive B-cell Non-Hodgkin lymphoma by anti-CD20 CARmRNA-
modified expanded natural killer cells in vitro and in NSG mice. Cancer
Immunol Res (2015) 3(4):333–44. doi:10.1158/2326-6066.CIR-14-0114
34. Töpfer K, Cartellieri M, Michen S, Wiedemuth R, Müller N, Lindemann D,
et al. DAP12-based activating chimeric antigen receptor for NK cell tumor
immunotherapy. J Immunol (2015) 194(7):3201–12. doi:10.4049/jimmunol.
1400330
35. Lang S, Vujanovic NL, Wollenberg B, Whiteside TL. Absence of B7.1-
CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur J
Immunol (1998) 28:780–6. doi:10.1002/(SICI)1521-4141(199803)28:03<780::
AID-IMMU780>3.3.CO;2-#
36. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al.
Licensing of natural killer cells by host major histocompatibility complex class
I molecules. Nature (2005) 436:709–13. doi:10.1038/nature03847
37. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer
cells overcomes inhibitory signals and induces specific killing of leukemic cells.
Blood (2005) 106:376–83. doi:10.1182/blood-2004-12-4797
38. Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, et al.
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors
costimulates natural killer cell activation to leukemia and neuroblastoma cells.
Clin Cancer Res (2009) 15:4857–66. doi:10.1158/1078-0432.CCR-08-2810
39. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, et al. Expres-
sion of chimeric antigen receptors in natural killer cells with a regulatory-
compliant non-viral method. Cancer Gene Ther (2010) 17:147–54. doi:10.1038/
cgt.2009.61
40. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger
B, et al. Engineering antigen-specific primary human NK cells against HER-2
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1955
Hermanson and Kaufman NK cell-based CARs
positive carcinomas. Proc Natl Acad Sci U S A (2008) 105:17481–6. doi:10.1073/
pnas.0804788105
41. Alsamah W, Romia Y. Modification of natural killer cells to target tumors. Int
J Pharm Clin Res (2014) 6(1):97–100.
42. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A
chimeric receptor with NKG2D specificity enhances natural killer cell activa-
tion and killing of tumor cells. Cancer Res (2013) 73:1777–86. doi:10.1158/
0008-5472.CAN-12-3558
43. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-
derived NK cells acquire functional receptors and cytolytic activity. J Immunol
(2005) 175:5095–103. doi:10.4049/jimmunol.175.8.5095
44. Woll PS, Grzywacz B, TianX,Marcus RK, KnorrDA,VernerisMR, et al. Human
embryonic stem cells differentiate into a homogeneous population of natural
killer cells with potent in vivo antitumor activity. Blood (2009) 113:6094–101.
doi:10.1182/blood-2008-06-165225
45. Ni Z, Knorr DA, Clouser CL, Hexum MK, Southern P, Mansky LM, et al.
Human pluripotent stem cells produce natural killer cells that mediate anti-
HIV-1 activity by utilizing diverse cellular mechanisms. J Virol (2011) 85:43–50.
doi:10.1128/JVI.01774-10
46. Ni Z, Knorr DA, Kaufman DS. Hematopoietic and nature killer cell develop-
ment from human pluripotent stem cells.Methods Mol Biol (2013) 1029:33–41.
doi:10.1007/978-1-62703-478-4_3
47. Eguizabal C, Zenarruzabeitia O, Monge J, Santos S, Vesga MA, Maruri N, et al.
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived
NK cells as an immunotherapeutic perspective. Front Immunol (2014) 5:439.
doi:10.3389/fimmu.2014.00439
48. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al.
Clinical-scale derivation of natural killer cells from human pluripotent stem
cells for cancer therapy. Stem Cells Transl Med (2013) 2:274–83. doi:10.5966/
sctm.2012-0084
49. Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric
receptor CD4ζ by natural killer cells derived from human pluripotent stem cells
improves in vitro activity but does not enhance suppression of HIV infection
in vivo. Stem Cells (2014) 32:1021–31. doi:10.1002/stem.1611
50. Wilber A, Linehan JL, Tian X, Woll PS, Morris JK, Belur LR, et al. Efficient and
stable transgene expression in human embryonic stem cells using transposon-
mediated gene transfer. Stem Cells (2007) 25:2919–27. doi:10.1634/stemcells.
2007-0026
51. Goodier MR, Londei M. CD28 is not directly involved in the response of
human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells.
Immunology (2004) 111:384–90. doi:10.1111/j.0019-2805.2004.01834.x
52. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion
of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res
(2009) 69:4010–7. doi:10.1158/0008-5472.CAN-08-3712
53. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson
JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation
of human natural killer cells. PLoS One (2012) 7:e30264. doi:10.1371/journal.
pone.0030264
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015Hermanson andKaufman. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1956
